TScan Therapeutics to Host Virtual KOL Event to Discuss Clinical Updates from the ALLOHA™ Phase 1 Trial and Heme Development Strategy
TScan Therapeutics (Nasdaq: TCRX) announces a virtual KOL event to discuss data from their ALLOHA™ Phase 1 heme trial presented at the ASH Annual Meeting and their clinical development strategy.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
TScan Therapeutics (Nasdaq: TCRX) announces a virtual KOL event to discuss data from their ALLOHA™ Phase 1 heme trial presented at the ASH Annual Meeting and their clinical development strategy. The event, scheduled for December 10 at 8:00 a.m. ET, will review preliminary results of TSC-100 and TSC-101 in patients with AML, ALL, and MDS undergoing allogeneic hematopoietic cell transplantation. The company will also provide updates on their PLEXI-T™ Phase 1 solid tumor trial and discuss potential registrational pathways following their FDA meeting.
Positive
- Initial FDA meeting completed regarding potential registrational pathway
- Multiple ongoing Phase 1 trials in both heme and solid tumors showing pipeline progress
Negative
- None.
Details
News Market Reaction – TCRX
The recorded move for TCRX in the trading session of this news was +1.68%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Company to also provide an update on PLEXI-T™ Phase 1 solid tumor trial
WALTHAM, Mass., Dec. 02, 2024 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients with cancer, today announced the Company will host a virtual key opinion leader (KOL) event to discuss data from the ALLOHA™ Phase 1 heme trial presented at the ASH Annual Meeting and the clinical development strategy for the heme program. Additionally, the Company will provide an update on its PLEXI-T Phase 1 solid tumor trial. The virtual event will take place on Tuesday, December 10, at 8:00 a.m. ET.
The event will provide an in-depth review of the oral presentation describing the preliminary results from TScan’s ongoing ALLOHA Phase 1 heme trial of TSC-100 and TSC-101 in patients with acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), and myelodysplastic syndrome (MDS) undergoing allogeneic hematopoietic cell transplantation (HCT) with reduced intensity conditioning. The Company will also provide updates with regards to a potential registrational path for the program following its initial meeting with the U.S. Food and Drug Administration (FDA), as well as future plans to expand the program.
Featured speakers include:
- Ran Reshef, M.D., M.Sc., Director of Translational Research, Blood and Marrow Transplantation Program, Columbia University Irving Medical Center
- Gavin MacBeath, Ph.D., Chief Executive Officer, TScan Therapeutics
- Chrystal U. Louis, M.D., Chief Medical Officer, TScan Therapeutics
- Shrikanta Chattopadhyay, M.D., Senior Vice President, Head of Translational Medicine, TScan Therapeutics
Registration for the live event can be found here. A replay will be made available on the “Events and Presentations” section of the Company’s investor relations website at ir.tscan.com.
About TScan Therapeutics, Inc.
TScan is a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients with cancer. The Company’s lead TCR-T therapy candidates are in development for the treatment of patients with hematologic malignancies to prevent relapse following allogeneic hematopoietic cell transplantation (the ALLOHATM Phase 1 heme trial). The Company has developed and continues to expand its ImmunoBank, the Company’s repository of therapeutic TCRs that recognize diverse targets and are associated with multiple HLA types, to provide customized multiplex TCR-T therapies for patients with a variety of cancers and is enrolling patients into its ongoing PLEXI-T Phase 1 solid tumor trial.
Contacts
Heather Savelle
TScan Therapeutics, Inc.
VP, Investor Relations
857-399-9840
hsavelle@tscan.com
Maghan Meyers
Argot Partners
212-600-1902
TScan@argotpartners.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.